A Phase 2 interventional study of Nicotinamide Riboside (NR) and Palacebo in Alzheimer Disease (AD), sponsored by Haukeland University Hospital. Recruiting at 2 sites in Norway. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Haukeland University Hospital · Phase 2, Interventional, and Treatment
The goal of this clinical trial is to learn if orally administered nicotinamide riboside works to slow the progression of early Alzheimer disease in adults. It will also learn about the safety of drug nicotinamide riboside. The main questions it aims to answer are:
Participants will:
3,965 studies on the registry are indexed under Alzheimer Disease; 926 are open to participants now.
This study's planned enrollment of 270 is above the median of 70 across 3,019 interventional studies indexed under Alzheimer Disease.
Browse Alzheimer Disease studies →Haukeland University Hospital is the lead sponsor of 284 studies on the registry; 59 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
MMSE and MoCA
Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Nicotinamide riboside, 2000 mg for the duration of the trial (104 weeks). Dosage form is capsules.
Dietary Supplement: Nicotinamide Riboside (NR)
Placebo capsules, no active ingredients.
Other: Palacebo
Nicotinamide Riboside 1000mg administered two times a day. Given as capsules. Duration of the trial; 104 weeks.
Also known as: NR, TruNiagen
Placebo drug, administered two times a day. Given as capsules. Duration of the trial; 104 weeks.
Disease severity assessed by the Clinical Dementia Rating scale (CDR) sum of boxes.
CDR is a scale assessing clinical impairment in AD. CDR integrates assessments from 3 domains of cognition (memory, orientation, judgment/problem-solving) and 3 domains of function (community affairs, home/hobbies, personal care). Following semi-structured caregiver interview and systematic participant examination, the rater assigns a score describing the participant's current performance level in each of these domains of life functioning. The "Sum of boxes" scoring methodology (CDR-SB) sums the score for each of the 6 domains and provides a value ranging from 0 to 18 with higher scores indicating greater impairment. Positive change from baseline indicates greater impairment.
Time frame: From baseline to the end of treatment at 104 weeks.
Change from baseline in the MoCA score at Week 104.
MoCA is a validated global measure of cognitive ability. The MoCA scale ranges from 0 - 30. Lower scores indicate cognitive impairment.
Time frame: From baseline to the end of treatment at 104 weeks.
Change from baseline in Amsterdam ADL scale short version (A-IADL-Q-SV) at Week 104.
The Amsterdam ADL scale short version (A-IADL-Q-SV) is a 30-item, proxy-completed, psychometrically validated instrument designed to measure functional decline in instrumental activities of daily living (IADL). Lower scores reflect greater impairment.
Time frame: From baseline to the end of treatment at 104 weeks
Change from baseline in delayed recall performance on the CERAD 10-Word List at Week 104
CERAD 10-Word List Test evaluates memory. Higher scores reflect better performance.
Time frame: From baseline to the end of treatment at 104 weeks.
Change from baseline in executive functioning as measured by Trail-Making Test Part B completion time at Week 104
Trail-Making Test B (TMT-B) measures executive function. Score = Time to Completion. Maximumt time in this trial is 360 sekunds. Longer time reflects greater impairment.
Time frame: From baseline to the end of treatment at 104 weeks.
Change from baseline in verbal fluency as measured by the COWAT (total correct words for F, A, S) at Week 104.
The Controlled Oral Word Association Test (COWAT) F A S version assesses verbal fluency. The total score is simply the count of all valid, non-repeated, rule-adherent words. Higher scores reflect better performance.
Time frame: From baseline to the end of treatment at 104 weeks.
Change from baseline in Neuropsychiatric Inventory-Questionnaire (NPI-Q) at Week 104.
The NPI-Q measures the burden of 12 neuropsychiatric symptoms of dementia: delusions, hallucinations, agitation/aggression, depression/dysphoria, anxiety, elation/euphoria, apathy/indifference, disinhibition, irritability/lability, motor disturbance, nighttime behaviors, and appetite/eating. Symptom severity is rated on a 3-point scale with higher scores indicating worse symptoms. Minimum score would be 0 and maximum score would be 36.
Time frame: From baseline to the end of treatment at 104 weeks.
Change from baseline in plasma p-tau217 levels at 104 weeks
Plasma phosphorylated tau at threonine 217 (p-tau217) is a blood-based biomarker of Alzheimer's disease pathology. Plasma p-tau217 concentration will be measured using a validated analytical assay. Changes in p-tau217 levels from baseline to Week 104 will be assessed as an exploratory biomarker outcome to evaluate potential treatment effects on Alzheimer's disease-related tau pathology.
Time frame: From baseline to end of treatment at week 104.
Change from baseline in plasma MTBR-tau243 levels at 104 weeks
Plasma microtubule-binding region tau fragment 243 (MTBR-tau243) concentration will be measured using a validated analytical assay. MTBR-tau243 is a biomarker associated with tau neurofibrillary tangle pathology in Alzheimer's disease. Change from baseline to Week 104 will be assessed as an exploratory biomarker outcome.
Time frame: From baseline to end of treatment at 104 weeks.
Frequency and severity of adverse events
The between-visit difference in incidence of treatment-associated mild/moderate/severe adverse events (AEs)
Time frame: From baseline to end of treatment at 104 weeks.
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nicotinamide-beta-riboside
Haukeland University Hospital →